Openly accessible

Aptamer therapeutics: the 21st century's magic bullet of nanomedicine

Shigdar, Sarah, Luczo, Jasmina, Wei, Ming Q, Bell, Richard, Danks, Andrew, Liu, Ke and Wei, Duan 2010, Aptamer therapeutics: the 21st century's magic bullet of nanomedicine, Open conference proceedings journal, vol. 1, pp. 118-124.

Attached Files
Name Description MIMEType Size Downloads
shigdar-aptamertherapeutics-2010.pdf Published version application/pdf 113.43KB 32

Title Aptamer therapeutics: the 21st century's magic bullet of nanomedicine
Author(s) Shigdar, Sarah
Luczo, Jasmina
Wei, Ming Q
Bell, Richard
Danks, Andrew
Liu, Ke
Wei, Duan
Journal name Open conference proceedings journal
Volume number 1
Start page 118
End page 124
Total pages 7
Publisher Bentham Science Publishers
Place of publication Bussum, The Netherlands
Publication date 2010
ISSN 2210-2892
Keyword(s) aptamer
SELEX
cancer
Summary Aptamers, also known as chemical antibodies, are short single-stranded DNA, RNA or peptide molecules. These molecules can fold into complex three-dimensional structures and bind to target molecules with high affinity and specificity. The nucleic acid aptamers are selected from combinatorial libraries by an iterative in vitro selection procedure known as systematic evolution of ligands by exponential enrichment (SELEX). As a new class of therapeutics and drug targeting entities, bivalent and multivalent aptamer-based molecules are emerging as highly attractive alternatives to monoclonal antibodies as targeted therapeutics.

Aptamers have several advantages, offering the possibility of overcoming limitations of antibodies: 1) they can be selected against toxic or non-immunogenic targets; 2) aptamers can be chemically modified by using modified nucleotides to enhance their stability in biological fluids or via incorporating reporter molecules, radioisotopes and functional groups for their detection and immobilization; 3) they have very low immunogenicity; 4) they display high stability at room temperature, in extreme pH, or solvent; 5) once selected, they can be chemically synthesized free from cell- culturederived contaminants, and they can be manufactured at any time, in large amounts, at relatively low cost and reproducibly; 6) they are smaller and thus can diffuse more rapidly into tissues and organs, leading to faster targeting in drug delivery; 7) they have lower molecular weight that can lead to faster body clearance, resulting in a low background noise for imaging and minimizing the radiation dose to the patient in diagnostic imaging. Thus, the high selectivity and sensitivity, ease of screening and production, chemical versatility as well as stability make aptamers a class of highly attractive agents for the development of novel therapeutics, targeted drug delivery vehicles and molecular imaging.

In the review, we will discuss the latest technological advances in developing aptamers, its application as a novel class of drug on its own, as well as in surface functionalization of both polymer nanoparticles or nanoliposomes in the treatment of cancer, viral and autoimmune diseases.
Language eng
Field of Research 100709 Nanomedicine
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
Persistent URL http://hdl.handle.net/10536/DRO/DU:30055456

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Access Statistics: 71 Abstract Views, 32 File Downloads  -  Detailed Statistics
Created: Tue, 27 Aug 2013, 12:50:51 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.